The steering committee is an independent committee that is evaluating Foxy-5's safety data regarding its side effect profile during the ongoing phase 2 study NeoFox. The conclusion from the committee remains thus from previous safety reviews.

“It is very gratifying that the side effect profile of Foxy-5 has been confirmed once again with a positive statement by the steering committee. We continue our development of the drug candidate Foxy-5 to introduce a new effective treatment with a good side effect profile in colon cancer. After the positive observations regarding reduced tumour burden, so-called down staging (in primary tumor and regional lymph nodes), we paused patient recruitment in 126 patients. Our goal is to produce a revised plan regarding the NeoFox study this year.” says CEO Pernilla Sandwall.

For further information:

Pernilla Sandwall, VD, WntResearch AB
e-post: pernilla.sandwall@wntresearch.com

About WntResearch

WntResearch is a biotech company in oncology that develops new therapies intended to prevent the meta-static process. The company's research is focused on studying the endogenous protein WNT5A, which in scientific studies has shown to affect tumour cells' ability to move and spread in the body. WntResearch drug candidate Foxy-5 is a peptide that mimics the function of WNT5A and is intended to reduce the mobili-ty and spread of cancer cells thus preventing metastases from occurring. Although current cancer treat-ment has become more effective, there are no effective ways to prevent the onset of metastases that cause about 90 percent of all cancer-related deaths. Foxy-5 has a unique mechanism of action and has shown a good safety profile with few side effects in two Phase I clinical trials. The safety and efficacy of Foxy-5 are now being evaluated in the ongoing Phase 2 clinical trial NeoFox, in patients with stage II-III colon cancer.

WntResearch is listed on the Spotlight Stock Market. For more information, please visit: www.wntresearch.com

Follow WntResearch on Linked in